Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoonRISe-2 intravesical TAR-210 in intermediate-risk non-muscle-invasive bladder cancer
MOH_2025-02-17_013913Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Erda-iDRS in bladder cancer and non-muscle-invasive bladder cancer (NMIBC), sponsored by Janssen Pharmaceutical. Started Feb 2025; status: active, not recruiting.
02
Drugs
Erda-iDRS
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on MOH_2025-02-17_013913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-02-17_013913.